We observed the mRNA expression levels of ITPRIPL1 varied significantly across clinicopathological stages in mesothelioma (MESO), LIHC, SKCM, thyroid carcinoma (THCA), and TGCT (Figure 1E) (P < 0.05). This evidence concerns the gene ITPRIPL1 and mesothelioma.